The Biotherapeutics Association of Australasia (BAA) is the peak body representing cellular therapy and tissue bankers in Australia and New Zealand.
Australasian Tissue Banks & Cell Therapy facilities associated with the BAA manufacture the following biotherapeutic products for implant:
- musculoskeletal tissues (e.g. bones, tendons, ligaments),
- cardiovascular tissues (e.g. heart valves, pericardium, vascular tissue),
- skin (e.g. split thickness allografts),
- amnion (e.g. membrane grafts) and
- cellular biotherapeutic products (e.g. mesenchymal stromal cells).
All of these products are derived from donors and manufactured in Australia/NZ. Member Tissue Banks are regulated and licensed by bodies such as the Therapeutics Goods Administration (TGA) and MedSafe New Zealand. Products also meet extensive tracking, traceability and biovigilance criteria to ensure they are of the highest quality and safety for recipients.
As part of their mandate, the BAA co-ordinate a conference annually, which this year will be held in Auckland (New Zealand) from the 1st -3rd November. SeerPharma is proud to sponsor, exhibit and will also be supporting the event with a presentation to delegates on:
- Updates to the new PIC/S Guide to GMP version 13,
- An overview of Risk Management in Tissue Banking
For more information on the BAA conference, please visit http://www.baa2017.org
